DK0789575T3 - Perifer-nerve-system-specifikke natriumkanaler, DNA kodende derfor, screening af lægemidler og fremgangsmåder til fremstilling og anvendelse deraf - Google Patents

Perifer-nerve-system-specifikke natriumkanaler, DNA kodende derfor, screening af lægemidler og fremgangsmåder til fremstilling og anvendelse deraf

Info

Publication number
DK0789575T3
DK0789575T3 DK95939723T DK95939723T DK0789575T3 DK 0789575 T3 DK0789575 T3 DK 0789575T3 DK 95939723 T DK95939723 T DK 95939723T DK 95939723 T DK95939723 T DK 95939723T DK 0789575 T3 DK0789575 T3 DK 0789575T3
Authority
DK
Denmark
Prior art keywords
methods
preparation
peripheral nerve
drug screening
pns
Prior art date
Application number
DK95939723T
Other languages
Danish (da)
English (en)
Inventor
Gail Mandel
Simon Halegoua
Laurence A Borden
Original Assignee
Nps Pharma Inc
Univ New York State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26989015&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0789575(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nps Pharma Inc, Univ New York State Res Found filed Critical Nps Pharma Inc
Application granted granted Critical
Publication of DK0789575T3 publication Critical patent/DK0789575T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
DK95939723T 1994-11-02 1995-11-02 Perifer-nerve-system-specifikke natriumkanaler, DNA kodende derfor, screening af lægemidler og fremgangsmåder til fremstilling og anvendelse deraf DK0789575T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33402994A 1994-11-02 1994-11-02
US48240195A 1995-06-07 1995-06-07
PCT/US1995/014251 WO1996014077A1 (en) 1994-11-02 1995-11-02 Peripheral nervous system specific sodium channels, dna encoding therefor, crystallization, x-ray diffraction, computer molecular modeling, rational drug design, drug screening, and methods of making and using thereof

Publications (1)

Publication Number Publication Date
DK0789575T3 true DK0789575T3 (da) 2009-01-12

Family

ID=26989015

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95939723T DK0789575T3 (da) 1994-11-02 1995-11-02 Perifer-nerve-system-specifikke natriumkanaler, DNA kodende derfor, screening af lægemidler og fremgangsmåder til fremstilling og anvendelse deraf

Country Status (13)

Country Link
US (5) US6110672A (pt)
EP (2) EP0789575B8 (pt)
JP (5) JP2000503521A (pt)
AT (1) ATE407207T1 (pt)
AU (1) AU697465B2 (pt)
CA (1) CA2204355C (pt)
DE (1) DE69535830D1 (pt)
DK (1) DK0789575T3 (pt)
ES (1) ES2314978T3 (pt)
MX (1) MX9703187A (pt)
NZ (1) NZ296748A (pt)
PT (1) PT789575E (pt)
WO (1) WO1996014077A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE407207T1 (de) * 1994-11-02 2008-09-15 Trophix Pharm Inc Natrium-ionenkanäle spezifisch für das periphäre nervensystem, dna welche diese kodiert, wirkstoff-suche und methoden zu deren herstellung und verwendung
US6184349B1 (en) 1995-10-11 2001-02-06 Syntex (Usa) Inc. Cloned peripheral nerve, tetrodotoxin-resistant sodium channel α-subunit
US6030810A (en) 1997-02-26 2000-02-29 Delgado; Stephen Gregory Cloned tetrodotoxin-sensitive sodium channel α-subunit and a splice variant thereof
EP0875570A3 (en) * 1997-05-01 1999-12-22 Smithkline Beecham Plc Neurodegenerative polypeptides HHPDZ65
CH693031A5 (de) * 1997-11-20 2003-01-31 Hoffmann La Roche Nucleinsäure, die einen Nervengewebe-Natriumkanal kodiert.
AU3908700A (en) * 1999-03-26 2000-10-16 Human Genome Sciences, Inc. 48 human secreted proteins
US7083777B1 (en) * 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
CA2394229C (en) 1999-11-26 2010-04-13 Mcgill University Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy
WO2002002608A2 (en) * 2000-07-05 2002-01-10 Neurosearch A/S NEW SODIUM CHANNEL (rNaV1.5a) AND USE THEREOF
GB0021617D0 (en) * 2000-09-02 2000-10-18 Imp College Innovations Ltd Diagnosis and treatment of cancer
AU2001294141A1 (en) * 2000-09-19 2002-04-02 Gbf Gesellschaft Fur Biotechnologische Forschung Mbh Crystalline fgf9 dimer and methods of use
DE10054878A1 (de) * 2000-11-06 2002-05-08 Boehringer Ingelheim Int Natriumkanäle vom Typus der peripheren Nerven
SV2003000753A (es) * 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
EP1468293A1 (en) * 2002-01-17 2004-10-20 EVOTEC Neurosciences GmbH Diagnostic and therapeutic use of the voltage-gated ion channel scn2a for neurodegenerative diseases
US9278088B2 (en) 2002-02-19 2016-03-08 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
US7659082B2 (en) 2002-02-19 2010-02-09 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
CA2474751A1 (en) 2002-02-25 2003-09-04 Vanderbilt University Expression system for human brain-specific voltage-gated sodium channel, type 1
WO2004050857A2 (en) * 2002-12-04 2004-06-17 Euro-Celtique S.A. Splice variant of human sodium iii channel (hnaiii18)
EP1638581A2 (en) * 2003-03-31 2006-03-29 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
WO2005069969A2 (en) * 2004-01-21 2005-08-04 University Of Utah Research Foundation Mutant sodium channel nav1.7 and methods related thereto
US20050201995A1 (en) * 2004-02-05 2005-09-15 Board Of Regents, The University Of Texas System Methods and compositions related to neuronal differentiation
US7485468B2 (en) 2004-10-15 2009-02-03 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
US8206726B2 (en) 2006-02-06 2012-06-26 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
US20100247435A1 (en) * 2007-06-14 2010-09-30 Erik Arstad Measurement of neural activity
US20120283116A1 (en) 2009-09-11 2012-11-08 Leppert Mark F Mutant Sodium Channel Nav1.7 and Methods Related Thereto
WO2013009945A1 (en) 2011-07-12 2013-01-17 The Brigham And Women's Hospital, Inc. Lipid-containing psa compositions, methods of isolation and methods of use thereof
WO2017031431A1 (en) 2015-08-19 2017-02-23 President And Fellows Of Harvard College Lipidated psa compositions and methods
EP3484441A4 (en) 2016-07-15 2020-03-18 President and Fellows of Harvard College GLYCOLIPID COMPOSITIONS AND METHODS OF USE

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL137318C (pt) 1964-06-09
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4500530A (en) * 1980-11-26 1985-02-19 Boucher John H Method of treating horses to inhibit or reduce increases in crenated red blood cells during exercise
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4766067A (en) 1985-05-31 1988-08-23 President And Fellows Of Harvard College Gene amplification
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US4921794A (en) 1987-01-14 1990-05-01 President And Fellows Of Harvard College T7 DNA polymerase
US4795699A (en) 1987-01-14 1989-01-03 President And Fellows Of Harvard College T7 DNA polymerase
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5142033A (en) 1988-09-23 1992-08-25 Hoffmann-La Roche Inc. Structure-independent DNA amplification by the polymerase chain reaction
US5091310A (en) 1988-09-23 1992-02-25 Cetus Corporation Structure-independent dna amplification by the polymerase chain reaction
US5066584A (en) 1988-09-23 1991-11-19 Cetus Corporation Methods for generating single stranded dna by the polymerase chain reaction
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US4994370A (en) 1989-01-03 1991-02-19 The United States Of America As Represented By The Department Of Health And Human Services DNA amplification technique
WO1990009441A1 (en) 1989-02-01 1990-08-23 The General Hospital Corporation Herpes simplex virus type i expression vector
WO1990009391A1 (en) * 1989-02-13 1990-08-23 Arch Development Corporation Nucleic acid encoding sodium channel protein
US5380836A (en) * 1989-02-13 1995-01-10 Arch Development Corporation Nucleic acid encoding sodium channel protein
DE69120699T2 (de) * 1990-03-08 1997-01-09 Fujisawa Pharmaceutical Co N-Monosubstituierte Cyclopentenylamine, ein Verfahren zu ihrer Herstellung, und ihre Verwendung als Medikament
IE911869A1 (en) 1990-06-01 1991-12-04 Regeneron Pharma A family of map2 protein kinases
DE69131321T2 (de) 1990-09-28 1999-12-16 F. Hoffmann-La Roche Ag, Basel Mutationen in der 5'-3'-exonukleaseaktivität thermostabiler dna-polymerasen
WO1992006693A1 (en) 1990-10-22 1992-04-30 Fox Chase Cancer Center Dna construct for providing rna therapy
AU2468992A (en) 1991-08-16 1993-03-16 General Hospital Corporation, The Method of gene delivery to post-mitotic cells
US5356777A (en) * 1992-10-01 1994-10-18 University Of Pittsburgh Methods of detecting periodic paralysis in horses
US5338671A (en) 1992-10-07 1994-08-16 Eastman Kodak Company DNA amplification with thermostable DNA polymerase and polymerase inhibiting antibody
US5340728A (en) 1992-12-09 1994-08-23 E. I. Du Pont De Nemours And Company Method for amplification of targeted segments of nucleic acid using nested polymerase chain reaction
WO1994014978A1 (de) 1992-12-18 1994-07-07 Strack Hans B Verbesserte ausbeuten von pcr-produkten in gegenwart von dna-einzelstrang bindendem protein und dessen präparation aus thermus flavus
ATE407207T1 (de) * 1994-11-02 2008-09-15 Trophix Pharm Inc Natrium-ionenkanäle spezifisch für das periphäre nervensystem, dna welche diese kodiert, wirkstoff-suche und methoden zu deren herstellung und verwendung

Also Published As

Publication number Publication date
EP1985703A2 (en) 2008-10-29
ATE407207T1 (de) 2008-09-15
US8012748B2 (en) 2011-09-06
EP1985703A3 (en) 2009-04-08
EP0789575B8 (en) 2009-01-14
JP2009055921A (ja) 2009-03-19
JP2009118844A (ja) 2009-06-04
ES2314978T3 (es) 2009-03-16
MX9703187A (es) 1998-02-28
US20030092645A1 (en) 2003-05-15
NZ296748A (en) 1999-11-29
EP0789575A4 (en) 2000-11-08
WO1996014077A1 (en) 1996-05-17
JP2000503521A (ja) 2000-03-28
JP2003047484A (ja) 2003-02-18
AU4143496A (en) 1996-05-31
EP0789575A1 (en) 1997-08-20
US6110672A (en) 2000-08-29
PT789575E (pt) 2008-12-15
US6703486B2 (en) 2004-03-09
EP0789575B1 (en) 2008-09-03
CA2204355C (en) 2001-01-16
CA2204355A1 (en) 1996-05-17
US20090029415A1 (en) 2009-01-29
AU697465B2 (en) 1998-10-08
US20090203122A1 (en) 2009-08-13
US20040229792A1 (en) 2004-11-18
DE69535830D1 (de) 2008-10-16
JP2007169286A (ja) 2007-07-05

Similar Documents

Publication Publication Date Title
DK0789575T3 (da) Perifer-nerve-system-specifikke natriumkanaler, DNA kodende derfor, screening af lægemidler og fremgangsmåder til fremstilling og anvendelse deraf
ATE380037T1 (de) Verfaheren zur durch rekombinante adeno- assoziierte virus-gerichtete gentherapie
LU91759I2 (fr) Denosumab et ses dérivés pharmaceutique acceptables (PROLIA®)
ATE345387T1 (de) Verbindungen und verfahren für therapie und diagnose von lungenkrebs
RU95115239A (ru) Аналог эритропоэтина
DE69709752D1 (de) Androgen rezeptor modulator verbindungen und verfahren
FI935174A0 (fi) Tumoeravstoetande antigenprekursorer, tumoeravstoetande antigener och anvaendning av dem
BR0009505A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
AP2000001934A0 (en) Antipicornaviral compounds, their preparation and use.
DK2157192T3 (da) Sammensætninger til diagnose og terapi af sygdomme forbundet med afvigende ekspression af futriner (R-spondiner)
DE59402826D1 (de) Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2151560T3 (es) Adn codificador de una subunidad alfa-1e de canales de calcio humanos.
DK11187D0 (da) Dna-sekvenser der koder for proteiner med husi-type i inhibitorers biologiske aktivitet, biotekniske fremgangsmaader til fremstilling af proteinerne o g farmaceutiske praeparater der indeholder dem
ATE361359T1 (de) Funktion und aktivität des viralen proteins r (vpr)
DE69837322D1 (de) Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
FI972170A0 (fi) Peptidejä, jotka kykenevät sitoutumaan GAP-proteiinin SH3-domeeniin, näitä peptidejä koodittavia nukleotidisekvenssejä, niiden valmistus ja käyttö
DK0781344T3 (da) Hidtil ukendt implantat og hidtil ukendt vektor til behandling af erhvervede sygdomme
EP0815240A4 (en) NOVEL KINASE-LIKE CYCLINE-LIKE PROTEINS AND METHODS OF APPLICATION THEREOF
WO1996021020A3 (en) Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases
ES2147725T3 (es) Moleculas de adn recombinantes que codifican una cadena del receptor del antigeno de celulas t, procedimiento de preparacion, anticuerpos y medicamentos que las contienen.
DK1000067T3 (da) Thiazolobenzoheterocycliske forbindelser, deres fremstilling og lægemidler indeholdende forbindelserne
SE9402332D0 (sv) Igf-1
Fuhr et al. Evaluation of commercial erythropoietin activity after preparative isoelectric focusing
MX9709390A (es) Cistatina e humana.
EP1329457A3 (en) Antipicornaviral compounds, their preparation and use